Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity 
Gold Prices Stabilize but Head for Worst Weekly Drop in Six Years Amid Iran War Inflation Fears 
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal 
U.S. Stock Futures Steady as Wall Street Retreats on Oil Volatility and Fed Rate Outlook 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Elliott Investment Management Takes Activist Stake in Align Technology 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Dollar Weakens as Middle East War Reshapes Global Rate Expectations 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
Oil Prices Slide as U.S. Eyes Iranian Supply Relief Amid Middle East Tensions 
U.S. Markets Post Fourth Straight Weekly Loss Amid Middle East Escalation 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
S&P 500 Rebounds After Netanyahu's Statements on Iran's Military Setbacks 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
Japan's Parliament Backs Dovish BOJ Board Members, Raising Questions on Rate Hike Path 
Asian Currencies Slide as Oil Prices Surge Amid U.S.-Israel-Iran Conflict 
Samsung Biologics Co. was revealed to have won a new CMO contract deal with Pfizer Ireland Pharmaceuticals. The order is said to be worth $183 million, which is equivalent to 15.4% of Samsung Biologic's total sales profits in 2021.
Samsung Biologics is currently the no. 1 contract drug maker in the world based on production capacity. It has bagged this huge contract manufacturing organization (CMO) order from the Ireland unit of Pfizer Inc. the deal just raised expectations that the biotech division of Samsung Group's orders for this year will reach a new record high.
As per The Korea Economic Daily, Samsung Biologics announced its new CMO order through a regulatory filing on Thursday, March 2. Although this was only revealed now, the actual order was made by Pfizer Ireland Pharmaceuticals Ringaskiddy on Feb. 28.
Then again, the biotech firm did not mention the name of the medicine that it will make for Pfizer. It was stated in the contract that the manufacturing will run from Feb. 20, 2023, to Dec. 31, 2029.
In any case, this is the first time that Samsung Biologics or any Korean company has signed a CMO deal with the New York-headquartered pharmaceutical and biotech firm. Korea Joongang Daily reported with the latest business announcement, Samsung Biologics now boasts of having seven of the world's top 10 largest pharmaceutical firms as clients.
The Korean biotech company was established in 2011, and it has started partial operation of its fourth factory in Songdo, Incheon, just recently. This facility will have the capacity to produce 240,000 liters when it goes into full operation in June. This is said to be the largest single pharma production facility in the world.
Meanwhile, Samsung Biologics is investing another KRW 7.5 trillion or about $5.7 billion to build four new plants inside a manufacturing complex near its existing plants in the Songdo region.
